Showing 7871-7880 of 21408 results for "".
- Are There Racial and Ethnic Differences in Medicare Costs for Older Adults with Dementia?https://reachmd.com/news/are-there-racial-and-ethnic-differences-in-medicare-costs-for-older-adults-with-dementia/2462384/In an analysis of information on Medicare beneficiaries with dementia, Medicare expenditures were higher for Black and Hispanic individuals compared with whites. The Journal of the American Ger
- In Sickness and in Health, Older Couples Mostly Make Medicare Moves Togetherhttps://reachmd.com/news/in-sickness-and-in-health-older-couples-mostly-make-medicare-moves-together/2462383/Newswise — Older Americans who enroll in Medicare, or change their coverage, do so as individuals, even if they’re married or live with a partner. But a new study suggests the need for more efforts to help both members of a couple weigh and choose their options together.T
- Arthritis Foundation Announces First-Ever Foundation-Directed Post-Traumatic Osteoarthritis Clinical Trialhttps://reachmd.com/news/arthritis-foundation-announces-first-ever-foundation-directed-post-traumatic-osteoarthritis-clinical-trial/2462374/The trial studying patients at risk of post-traumatic knee osteoarthritis involves scientists at nine world-class institutions.ATLANTA, Oct. 12, 2023 /PRNewswire/ -- Today, World Arthritis Day, the Arthritis Foundation a
- Gene Therapy Is Now First FDA-Approved Treatment for Rare and Fatal CNS Disorderhttps://reachmd.com/news/gene-therapy-is-now-first-fda-approved-treatment-for-rare-and-fatal-cns-disorder/2462368/A genetic medicine at the heart of a $387 million Kyowa Kirin acquisition has won FDA approval, a regulatory decision that makes the one-time treatment the first approved therapy for the rare inherited disorder
- Deuruxolitinib Demonstrates Efficacy, Tolerability in Patients with Moderate to Severe AAhttps://reachmd.com/news/deuruxolitinib-demonstrates-efficacy-tolerability-in-patients-with-moderate-to-severe-aa/2462364/Woman experiences hair loss | Image Credit: Siam - stock.adobe.comPosters presented at the 2024 American Academy of Dermatology Annual Meeting
- Bayer Menopause Drug Meets Key Goal in Late-Stage Trialhttps://reachmd.com/news/bayer-menopause-drug-meets-key-goal-in-late-stage-trial/2462370/Bayer said investigational drug elinzanetant met its primary goal by reducing symptoms linked to menopause in a late-stage clinical trial, paving the way for submissions to health authorities for approval. The German pharmaceutical-and-agricultural group said Tuesday that elinzanetant sho
- Researchers Show How Neurochemicals Affect fMRI Readingshttps://reachmd.com/news/researchers-show-how-neurochemicals-affect-fmri-readings/2462361/A landmark study, led by Yen-Yu Ian Shih, PhD, professor of neurology and associate director of UNC’s Biomedical Research Imaging Center, could alter how researchers interpret results from functional magnetic resonance imaging.
- Two Pediatric Medical Device Companies Receive Prestigious Award at MedTech Color Edition of Make Your Medical Device Pitch For Kids!™ competitionhttps://reachmd.com/news/two-pediatric-medical-device-companies-receive-prestigious-award-at-medtech-color-edition-of-make-your-medical-device-pitch-for-kidstm-competition/2462351/Alliance for Pediatric Device Innovation (APDI), a federally funded consortium led by Children’s National Hospital, and member MedTech Color announce the winners of the latest Make Your Medical Device Pitch for Kids!™ competitio
- COVID-19 Pandemic Could Have Led to 20,000 Prostate Cancer Diagnosis Being Missedhttps://reachmd.com/news/covid-19-pandemic-could-have-led-to-20000-prostate-cancer-diagnosis-being-missed/2462360/Prostate cancer diagnoses in 20,000 men could have been missed due to the COVID-19 pandemic, finds a new study published in BJU International from
- Shaperon Enrolls First Patient in Phase 2 Clinical Trial for Atopic Dermatitis Therapy 'Nugel'https://reachmd.com/news/shaperon-enrolls-first-patient-in-phase-2-clinical-trial-for-atopic-dermatitis-therapy-nugel/2462439/Shaperon announced the enrollment of the first patient in the phase 2 clinical trial for atopic dermatitis treatment candidate Nugel. The trial will evaluate the efficacy of Nugel in improving the Eczema Area Severity Index (EASI) across a cohort of 210 patients with mild to moderate atop